Innate immune responses in hepatitis B virus (HBV) infection

Virology Journal

Volumn 11, Issue 1, 2014, Pages

  Busca, Aurelia ^a   Kumar, Ashok ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

Author keywords

Cytokines; HBV; Innate immunity; Interferon response; RIG I; TLRs

Indexed keywords

ANIMALS; DISEASE MODELS, ANIMAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNE EVASION; IMMUNITY, INNATE; MICE; MICE, TRANSGENIC; PAN TROGLODYTES;

EID: 84893637808     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-11-22     Document Type: Review

References (60)

1. Natural history of chronic hepatitis B. McMahon BJ, Clin Liver Dis 2010 14 3 381 396 10.1016/j.cld.2010.05.007 20638020
2. Treatment of chronic hepatitis B. Yuen MF, Lai CL, Lancet Infect Dis 2001 1 4 232 241 10.1016/S1473-3099(01)00118-9 11871510 (Pubitemid 33586055)
3. Management of viral hepatitis B. Pramoolsinsup C, J Gastroenterol Hepatol 2002 17 Suppl 125 S145 12000599
4. Pathogenesis of hepatitis B virus infection. Chisari FV, Isogawa M, Wieland SF, Pathol Biol (Paris) 2010 58 4 258 266 10.1016/j.patbio.2009.11.001 20116937
5. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, Fu L, Song M, Chen P, Gao W, Ren B, Sun Y, Cai T, Feng X, Sui J, Li W, Elife 2012 1 00049 10.7554/eLife.00049 23150796
6. High-level hepatitis B virus replication in transgenic mice. Guidotti LG, Matzke B, Schaller H, Chisari FV, J Virol 1995 69 10 6158 6169 7666518
7. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV, Immunity 1996 4 1 25 36 10.1016/S1074-7613(00)80295-2 8574849 (Pubitemid 26054933)
8. Hepatitis B virus transgenic mice: models of viral immunobiology and pathogenesis. Chisari FV, Curr Top Microbiol Immunol 1996 206 149 173 8608715 (Pubitemid 26025611)
9. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus. Tsuge M, Hiraga N, Takaishi H, Noguchi C, Oga H, Imamura M, Takahashi S, Iwao E, Fujimoto Y, Ochi H, Chayama K, Tateno C, Yoshizato K, Hepatology 2005 42 5 1046 1054 10.1002/hep.20892 16250045 (Pubitemid 43112671)
10. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. Maini MK, Boni C, Lee CK, Larrubia JR, Reignat S, Ogg GS, King AS, Herberg J, Gilson R, Alisa A, Williams R, Vergani D, Naoumov NV, Ferrari C, Bertoletti A, J Exp Med 2000 191 8 1269 1280 10.1084/jem.191.8.1269 10770795 (Pubitemid 30227116)
11. Toll-like receptors, RIG-I-like RNA helicases and the antiviral innate immune response. Thompson AJ, Locarnini SA, Immunol Cell Biol 2007 85 6 435 445 10.1038/sj.icb.7100100 17667934 (Pubitemid 47367510)
12. Antiviral signaling through pattern recognition receptors. Kawai T, Akira S, J Biochem 2007 141 2 137 145 17190786 (Pubitemid 46775751)
13. Viruses and interferon: a fight for supremacy. Katze MG, He Y, Gale M Jr, Nat Rev Immunol 2002 2 9 675 687 10.1038/nri888 12209136 (Pubitemid 37328725)
14. High levels of viral replication during acute hepatitis B infection predict progression to chronicity. Fong TL, Di Bisceglie AM, Biswas R, Waggoner JG, Wilson L, Claggett J, Hoofnagle JH, J Med Virol 1994 43 2 155 158 10.1002/jmv.1890430210 8083663 (Pubitemid 24236656)
15. Viral clearance without destruction of infected cells during acute HBV infection. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV, Science 1999 284 5415 825 829 10.1126/science.284.5415.825 10221919 (Pubitemid 29291352)
16. Genomic analysis of the host response to hepatitis C virus infection. Su AI, Pezacki JP, Wodicka L, Brideau AD, Supekova L, Thimme R, Wieland S, Bukh J, Purcell RH, Schultz PG, Chisari FV, Proc Natl Acad Sci U S A 2002 99 24 15669 15674 10.1073/pnas.202608199 12441396 (Pubitemid 35403989)
17. Genomic analysis of the host response to hepatitis B virus infection. Wieland S, Thimme R, Purcell RH, Chisari FV, Proc Natl Acad Sci U S A 2004 101 17 6669 6674 10.1073/pnas.0401771101 15100412 (Pubitemid 38586032)
18. Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines. McClary H, Koch R, Chisari FV, Guidotti LG, J Virol 2000 74 5 2255 2264 10.1128/JVI.74.5.2255-2264.2000 10666256 (Pubitemid 30091480)
19. Activation of pattern recognition receptor-mediated innate immunity inhibits the replication of hepatitis B virus in human hepatocyte-derived cells. Guo H, Jiang D, Ma D, Chang J, Dougherty AM, Cuconati A, Block TM, Guo JT, J Virol 2009 83 2 847 858 10.1128/JVI.02008-08 18971270
20. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. Isogawa M, Robek MD, Furuichi Y, Chisari FV, J Virol 2005 79 11 7269 7272 10.1128/JVI.79.11.7269-7272.2005 15890966 (Pubitemid 40677357)
21. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann KA, Purcell RH, Chisari FV, J Virol 2003 77 1 68 76 10.1128/JVI.77.1.68- 76.2003 12477811 (Pubitemid 36004947)
22. Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. Cavanaugh VJ, Guidotti LG, Chisari FV, J Virol 1997 71 4 3236 3243 9060687 (Pubitemid 27119971)
23. Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice. Kimura K, Kakimi K, Wieland S, Guidotti LG, Chisari FV, J Virol 2002 76 21 10702 10707 10.1128/JVI.76.21.10702-10707.2002 12368312 (Pubitemid 35176186)
24. Activated intrahepatic antigen-presenting cells inhibit hepatitis B virus replication in the liver of transgenic mice. Kimura K, Kakimi K, Wieland S, Guidotti LG, Chisari FV, J Immunol 2002 169 9 5188 5195 12391236 (Pubitemid 35217189)
25. Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hosel M, Quasdorff M, Wiegmann K, Webb D, Zedler U, Broxtermann M, Tedjokusumo R, Esser K, Arzberger S, Kirschning CJ, Langenkamp A, Falk C, Buning H, Rose-John S, Protzer U, Hepatology 2009 50 6 1773 1782 10.1002/hep.23226 19937696
26. Toll-like receptor-induced innate immune responses in non-parenchymal liver cells are cell type-specific. Wu J, Meng Z, Jiang M, Zhang E, Trippler M, Broering R, Bucchi A, Krux F, Dittmer U, Yang D, Roggendorf M, Gerken G, Lu M, Schlaak JF, Immunology 2010 129 3 363 374 10.1111/j.1365-2567.2009.03179.x 19922426
27. Interleukin-1 and tumor necrosis factor-alpha trigger restriction of hepatitis B virus infection via a cytidine deaminase AID. Watashi K, Liang G, Iwamoto M, Marusawa H, Uchida N, Daito T, Kitamura K, Muramatsu M, Ohashi H, Kiyohara T, Suzuki R, Li J, Tong S, Tanaka Y, Murata K, Aizaki H, Wakita T, J Biol Chem 2013 288 44 31715 10.1074/jbc.M113.501122 24025329
28. Cytokine and chemokine responses in the acute phase of hepatitis B virus replication in naive and previously vaccinated blood and plasma donors. Keating SM, Heitman JD, Wu S, Deng X, Stramer SL, Kuhns MC, Mullen C, Norris PJ, Busch MP, J Infect Dis 2013 [Epub ahead of print]
29. Hepatitis B virus surface antigen impairs myeloid dendritic cell function: a possible immune escape mechanism of hepatitis B virus. Op den Brouw ML, Binda RS, van Roosmalen MH, Protzer U, Janssen HL, van der Molen RG, Woltman AM, Immunology 2009 126 2 280 289 10.1111/j.1365-2567.2008.02896.x 18624732
30. Hepatitis B virus lacks immune activating capacity, but actively inhibits plasmacytoid dendritic cell function. Woltman AM, Op den Brouw ML, Biesta PJ, Shi CC, Janssen HL, PLoS One 2011 6 1 15324 10.1371/journal.pone.0015324 21246041
31. Altered functions of plasmacytoid dendritic cells and reduced cytolytic activity of natural killer cells in patients with chronic HBV infection. Martinet J, Dufeu-Duchesne T, Bruder Costa J, Larrat S, Marlu A, Leroy V, Plumas J, Aspord C, Gastroenterology 2012 143 6 1586 1596 e8 10.1053/j.gastro.2012.08. 046 22960656
32. Circulating and liver resident CD4 + CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. Xu D, Fu J, Jin L, Zhang H, Zhou C, Zou Z, Zhao JM, Zhang B, Shi M, Ding X, Tang Z, Fu YX, Wang FS, J Immunol 2006 177 1 739 747 16785573 (Pubitemid 43939189)
33. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Stoop JN, van der Molen RG, Baan CC, van der Laan LJ, Kuipers EJ, Kusters JG, Janssen HL, Hepatology 2005 41 4 771 778 10.1002/hep.20649 15791617 (Pubitemid 40462939)
34. Human plasmacytoid-derived dendritic cells and the induction of T-regulatory cells. Gilliet M, Liu YJ, Hum Immunol 2002 63 12 1149 1155 10.1016/S0198-8859(02)00753-X 12480258 (Pubitemid 36025989)
35. Human plasmacytoid dendritic cells from patients with chronic hepatitis B virus infection induce the generation of a higher proportion of CD4(+) and CD25(+) regulatory T cells compared with healthy patients. Hong J, Gong ZJ, Hepatol Res 2008 38 4 362 373 10.1111/j.1872-034X.2007.00279.x 18021229 (Pubitemid 351321179)
36. Circulating CD4+ CD25+ regulatory T cells correlate with chronic hepatitis B infection. Peng G, Li S, Wu W, Sun Z, Chen Y, Chen Z, Immunology 2008 123 1 57 65 10.1111/j.1365-2567.2007.02691.x 17764450 (Pubitemid 350255997)
37. Imbalance between circulating CD4(+) regulatory T and conventional T lymphocytes in patients with HBV-related acute-on-chronic liver failure. Dong X, Gong Y, Zeng H, Hao Y, Wang X, Hou J, Wang J, Li J, Zhu Y, Liu H, Han J, Zhou H, Shen L, Gao T, Zhou T, Yang S, Li S, Chen Y, Meng Q, Li H, Liver Int 2013 33 10 1517 1526 23869954
38. Hepatitis B core antigen stimulates interleukin-10 secretion by both T cells and monocytes from peripheral blood of patients with chronic hepatitis B virus infection. Hyodo N, Nakamura I, Imawari M, Clin Exp Immunol 2004 135 3 462 466 10.1111/j.1365-2249.2003.02376.x 15008979 (Pubitemid 38297147)
39. Chemokine-directed immune cell infiltration in acute and chronic liver disease. Karlmark KR, Wasmuth HE, Trautwein C, Tacke F, Expert Rev Gastroenterol Hepatol 2008 2 2 233 242 10.1586/17474124.2.2.233 19072358
40. The CD14+ CD16+ blood monocytes: their role in infection and inflammation. Ziegler-Heitbrock L, J Leukoc Biol 2007 81 3 584 592 17135573 (Pubitemid 46393535)
41. Hyper-activated pro-inflammatory CD16 monocytes correlate with the severity of liver injury and fibrosis in patients with chronic hepatitis B. Zhang JY, Zou ZS, Huang A, Zhang Z, Fu JL, Xu XS, Chen LM, Li BS, Wang FS, PLoS One 2011 6 3 17484 10.1371/journal.pone.0017484 21390263
42. Functional contribution of elevated circulating and hepatic non-classical CD14CD16 monocytes to inflammation and human liver fibrosis. Zimmermann HW, Seidler S, Nattermann J, Gassler N, Hellerbrand C, Zernecke A, Tischendorf JJ, Luedde T, Weiskirchen R, Trautwein C, Tacke F, PLoS One 2010 5 6 11049 10.1371/journal.pone.0011049 20548789
43. The trafficking of natural killer cells. Gregoire C, Chasson L, Luci C, Tomasello E, Geissmann F, Vivier E, Walzer T, Immunol Rev 2007 220 169 182 10.1111/j.1600-065X.2007.00563.x 17979846 (Pubitemid 350045566)
44. Natural killer cells and natural killer T cells. Seaman WE, Arthritis Rheum 2000 43 6 1204 1217 10.1002/1529-0131(200006)43:6<1204::AID-ANR3>3. 0.CO;2-I 10857779 (Pubitemid 30416305)
45. Early kinetics of innate and adaptive immune responses during hepatitis B virus infection. Fisicaro P, Valdatta C, Boni C, Massari M, Mori C, Zerbini A, Orlandini A, Sacchelli L, Missale G, Ferrari C, Gut 2009 58 7 974 982 10.1136/gut.2008.163600 19201769
46. Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. Micco L, Peppa D, Loggi E, Schurich A, Jefferson L, Cursaro C, Panno AM, Bernardi M, Brander C, Bihl F, Andreone P, Maini MK, J Hepatol 2013 58 2 225 233 10.1016/j.jhep.2012. 09.029 23046671
47. Profiles of NK, NKT cell activation and cytokine production following vaccination against hepatitis B. Albarran B, Goncalves L, Salmen S, Borges L, Fields H, Soyano A, Montes H, Berrueta L, APMIS 2005 113 7-8 526 535 16086823 (Pubitemid 41081477)
48. Natural killer T cell activation inhibits hepatitis B virus replication in vivo. Kakimi K, Guidotti LG, Koezuka Y, Chisari FV, J Exp Med 2000 192 7 921 930 10.1084/jem.192.7.921 11015434
49. Activating immunity in the liver. II. IFN-beta attenuates NK cell-dependent liver injury triggered by liver NKT cell activation. Trobonjaca Z, Kroger A, Stober D, Leithauser F, Moller P, Hauser H, Schirmbeck R, Reimann J, J Immunol 2002 168 8 3763 3770 11937527 (Pubitemid 34298375)
50. Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Oliviero B, Varchetta S, Paudice E, Michelone G, Zaramella M, Mavilio D, De Filippi F, Bruno S, Mondelli MU, Gastroenterology 2009 137 3 1151 1160 1160.e1-7 10.1053/j.gastro.2009.05.047 19470388
51. Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B. Tjwa ET, van Oord GW, Hegmans JP, Janssen HL, Woltman AM, J Hepatol 2011 54 2 209 218 10.1016/j.jhep.2010.07.009 21095036
52. Impairment of the retinoic acid-inducible gene-I-IFN-beta signaling pathway in chronic hepatitis B virus infection. Zhao G, An B, Zhou H, Wang H, Xu Y, Xiang X, Dong Z, An F, Yu D, Wang W, Bao S, Xie Q, Int J Mol Med 2012 30 6 1498 1504 22992810
53. Hepatitis B virus polymerase blocks pattern recognition receptor signaling via interaction with DDX3: implications for immune evasion. Wang H, Ryu WS, PLoS Pathog 2010 6 7 1000986 10.1371/journal.ppat.1000986 20657822
54. Hepatitis B virus polymerase inhibits RIG-I- and Toll-like receptor 3-mediated beta interferon induction in human hepatocytes through interference with interferon regulatory factor 3 activation and dampening of the interaction between TBK1/IKKepsilon and DDX3. Yu S, Chen J, Wu M, Chen H, Kato N, Yuan Z, J Gen Virol 2010 91 Pt 8 2080 2090 20375222
55. Hepatitis B virus X protein suppresses virus-triggered IRF3 activation and IFN-beta induction by disrupting the VISA-associated complex. Wang X, Li Y, Mao A, Li C, Li Y, Tien P, Cell Mol Immunol 2010 7 5 341 348 10.1038/cmi.2010.36 20711230
56. Hepatitis B virus regulatory HBx protein binds to adaptor protein IPS-1 and inhibits the activation of beta interferon. Kumar M, Jung SY, Hodgson AJ, Madden CR, Qin J, Slagle BL, J Virol 2011 85 2 987 995 10.1128/JVI.01825-10 21068253
57. The hepatitis B virus X protein disrupts innate immunity by downregulating mitochondrial antiviral signaling protein. Wei C, Ni C, Song T, Liu Y, Yang X, Zheng Z, Jia Y, Yuan Y, Guan K, Xu Y, Cheng X, Zhang Y, Yang X, Wang Y, Wen C, Wu Q, Shi W, Zhong H, J Immunol 2010 185 2 1158 1168 10.4049/jimmunol.0903874 20554965
58. Viral recognition by Toll-like receptors. Barton GM, Semin Immunol 2007 19 1 33 40 10.1016/j.smim.2007.01.003 17336545 (Pubitemid 46498754)
59. Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Wu J, Lu M, Meng Z, Trippler M, Broering R, Szczeponek A, Krux F, Dittmer U, Roggendorf M, Gerken G, Schlaak JF, Hepatology 2007 46 6 1769 1778 10.1002/hep.21897 17929296
60. Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Wu J, Meng Z, Jiang M, Pei R, Trippler M, Broering R, Bucchi A, Sowa JP, Dittmer U, Yang D, Roggendorf M, Gerken G, Lu M, Schlaak JF, Hepatology 2009 49 4 1132 1140 10.1002/hep.22751 19140219